Related Experiment Video
Updated: Apr 12, 2026

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
Published on: March 17, 2023
Tartaric Acid Enhances Adrenergic Receptor Activity: Test of a General Theory of Extracellular Aminergic GPCR
Robert Root-Bernstein1, Jenna Fewins, Patrick F Dillon
1Department of Physiology, Michigan State University, East Lansing, MI 48824, USA. rootbern@msu.edu.
Abstract:
Several different classes of compounds enhance the potency of aminergic receptor ligands three-fold or more and increase their duration of activity up to ten-fold. These enhancers include the vitamins ascorbic acid and folic acid, chelators such as ethylenediaminetetraacetic acid, corticosteroids, and opioids, opiates and opiate antagonists. We have previously demonstrated that all of these classes of enhancers share a common molecular motif consisting of a linear array of two hydroxyls and a carbonyl. We demonstrate here that because of this common molecular motif, all compounds known to enhance aminergic receptor ligands bind to highly conserved regions of the first or second extracellular loops of aminergic receptors at physiologically or pharmacologically relevant concentrations. These compounds also bind directly to aminergic ligands with significant specificity and affinity. These results suggest three very simple, complementary methods for screening for novel extracellular aminergic receptor enhancers: 1) in silico screening for the presence of the common aminergic receptor enhancer motif; 2) screening for binding to the aminergic ligand of choice; and 3) screening for binding to receptor peptides representing the enhancer binding site on the receptor. Using these three complementary methods, we predict a new class of enhancers (tartaric acids) and demonstrate the predicted enhancement in an in vitro smooth muscle assay.
More Related Videos
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
09:39Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
Published on: January 27, 2014
Related Concept Videos
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...